PL2676953T3 - Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego - Google Patents
Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowegoInfo
- Publication number
- PL2676953T3 PL2676953T3 PL13177190T PL13177190T PL2676953T3 PL 2676953 T3 PL2676953 T3 PL 2676953T3 PL 13177190 T PL13177190 T PL 13177190T PL 13177190 T PL13177190 T PL 13177190T PL 2676953 T3 PL2676953 T3 PL 2676953T3
- Authority
- PL
- Poland
- Prior art keywords
- ethyl
- benzyloxyimino
- azetidine
- trifluoromethyl
- cyclohexyl
- Prior art date
Links
- KIHYPELVXPAIDH-UHFFFAOYSA-N 1-[[4-[n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(C)=NOCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20305308P | 2008-12-18 | 2008-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2676953T3 true PL2676953T3 (pl) | 2017-09-29 |
Family
ID=42236293
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13177190T PL2676953T3 (pl) | 2008-12-18 | 2009-12-16 | Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego |
| PL09793413T PL2379497T3 (pl) | 2008-12-18 | 2009-12-16 | Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09793413T PL2379497T3 (pl) | 2008-12-18 | 2009-12-16 | Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | US20120115840A1 (pl) |
| EP (2) | EP2676953B1 (pl) |
| JP (1) | JP5627597B2 (pl) |
| KR (5) | KR20110096584A (pl) |
| CN (2) | CN102256943A (pl) |
| AR (3) | AR074694A1 (pl) |
| AU (1) | AU2009335924B2 (pl) |
| BR (1) | BRPI0923176B8 (pl) |
| CA (2) | CA2747437C (pl) |
| CL (1) | CL2011001490A1 (pl) |
| CO (1) | CO6390104A2 (pl) |
| CY (2) | CY1114662T1 (pl) |
| DK (2) | DK2676953T3 (pl) |
| EC (1) | ECSP11011210A (pl) |
| ES (2) | ES2631203T3 (pl) |
| HR (2) | HRP20131106T1 (pl) |
| HU (1) | HUE034819T2 (pl) |
| IL (3) | IL253845B (pl) |
| JO (1) | JO2894B1 (pl) |
| LT (1) | LT2676953T (pl) |
| MA (1) | MA32961B1 (pl) |
| MX (1) | MX2011006609A (pl) |
| MY (1) | MY152669A (pl) |
| NZ (1) | NZ593061A (pl) |
| PE (2) | PE20120336A1 (pl) |
| PL (2) | PL2676953T3 (pl) |
| PT (2) | PT2676953T (pl) |
| RS (2) | RS53041B (pl) |
| RU (1) | RU2518114C3 (pl) |
| SG (1) | SG171785A1 (pl) |
| SI (2) | SI2379497T1 (pl) |
| TW (2) | TWI591055B (pl) |
| UY (1) | UY32330A (pl) |
| WO (1) | WO2010080409A1 (pl) |
| ZA (1) | ZA201103709B (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA114283C2 (uk) * | 2011-01-07 | 2017-05-25 | Новартіс Аг | Композиції імуносупресантів |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| US20170027906A1 (en) | 2014-04-10 | 2017-02-02 | Philippe Michel Rene Bouillot | Immunosuppressant formulation |
| CN106456552A (zh) * | 2014-04-10 | 2017-02-22 | 诺华股份有限公司 | S1p调节剂的立即释放剂量方案 |
| WO2016135644A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| EP3400211A1 (en) | 2016-01-04 | 2018-11-14 | Auspex Pharmaceuticals, Inc. | Azetidine modulators of the sphingosine 1-phosphate receptor |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| US11958805B2 (en) * | 2017-03-09 | 2024-04-16 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| MX2020007270A (es) * | 2017-09-27 | 2020-08-17 | Novartis Ag | Formulacion parenteral que comprende siponimod. |
| CN111405897A (zh) | 2017-09-27 | 2020-07-10 | 雷迪博士实验室有限公司 | 辛波莫德、其盐及其固态形式的制备方法 |
| EP3687531A1 (en) | 2017-09-29 | 2020-08-05 | Novartis AG | Dosing regimen of siponimod |
| MX2020007268A (es) | 2017-09-29 | 2020-08-17 | Novartis Ag | Regimen de dosificacion de siponimod. |
| WO2019144094A1 (en) | 2018-01-22 | 2019-07-25 | Teva Pharmaceuticals International Gmbh | Crystalline siponimod fumaric acid and polymorphs thereof |
| CN110776450B (zh) * | 2018-07-27 | 2022-09-27 | 广东东阳光药业有限公司 | 一种辛波莫德晶型及其制备方法 |
| KR20200072795A (ko) | 2018-12-13 | 2020-06-23 | 고려대학교 산학협력단 | 옥시이미노메틸벤젠 유도체를 유효성분으로 포함하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물 |
| CN111484434A (zh) * | 2019-01-29 | 2020-08-04 | 东莞市东阳光仿制药研发有限公司 | 一种辛波莫德晶型及其制备方法 |
| WO2020161632A1 (en) * | 2019-02-07 | 2020-08-13 | Dr. Reddy’S Laboratories Limited | Crystalline solid forms of siponimod |
| US20220144768A1 (en) * | 2019-02-27 | 2022-05-12 | Dr. Reddy's Laboratories Limited | Solid state forms of siponimod |
| EP3947370A4 (en) * | 2019-03-28 | 2022-12-28 | 1st Biotherapeutics, Inc. | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof |
| EP3972954A1 (en) | 2019-05-21 | 2022-03-30 | Synthon B.V. | Siponimod maleic acid and fumaric acid salt |
| CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| GB202002560D0 (en) * | 2020-02-24 | 2020-04-08 | Johnson Matthey Plc | Crystalline forms of voxelotor, and processes for the preparation thereof |
| EP4139282A2 (en) * | 2020-05-29 | 2023-03-01 | Cipla Limited | Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof |
| EP4217341A1 (en) | 2020-09-25 | 2023-08-02 | Synthon B.V. | Siponimod salts and cocrystals |
| CN116456977A (zh) * | 2020-09-25 | 2023-07-18 | 斯索恩有限公司 | 西尼莫德盐和共晶 |
| CN112402610A (zh) * | 2020-11-20 | 2021-02-26 | 睿阜隆(杭州)生物医药有限公司 | 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途 |
| WO2022127863A1 (zh) * | 2020-12-16 | 2022-06-23 | 苏州晶云药物科技股份有限公司 | 一种羧酸类化合物半富马酸盐的晶型及其制备方法 |
| US20240150282A1 (en) | 2021-03-26 | 2024-05-09 | Olon S.P.A. | Novel crystalline compound of siponimod hemifumarate |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| ES2073868T3 (es) * | 1991-06-04 | 1995-08-16 | Fujisawa Pharmaceutical Co | Una composicion profilactica/terapeutica para la pleuroneumonia del cerdo. |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (pl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| DE69430575T2 (de) * | 1993-06-08 | 2002-10-02 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoretisches system |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| KR100437582B1 (ko) | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| PT916651E (pt) * | 1996-04-04 | 2004-01-30 | Sankyo Co | DERIVADOS DE áCIDO FENILALQUILCARBOXILICO |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| ATE300957T1 (de) | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| AU766081B2 (en) | 1999-03-30 | 2003-10-09 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| CA2433181C (en) * | 2000-12-29 | 2005-11-22 | Pfizer Limited | Amlodipine hemifumarate |
| US20030118078A1 (en) * | 2001-08-10 | 2003-06-26 | Carlson Eric D. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CA2479668A1 (en) * | 2002-03-20 | 2003-10-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
| US6900206B2 (en) * | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2004110330A1 (en) | 2003-06-13 | 2004-12-23 | Stephen Dichiera | Adjustable bed support and bed |
| AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| CN102600472A (zh) * | 2004-11-29 | 2012-07-25 | 诺瓦提斯公司 | S1p受体激动剂的剂量方案 |
| RU2008107873A (ru) * | 2005-08-04 | 2009-09-10 | Новартис АГ (CH) | Новые соединения |
| GT200600350A (es) * | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| US20060223820A1 (en) * | 2006-03-21 | 2006-10-05 | Chemagis Ltd. | Crystalline aripiprazole salts and processes for preparation and purification thereof |
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| AU2007323465B2 (en) * | 2006-11-07 | 2011-08-04 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-12-16 KR KR1020117016548A patent/KR20110096584A/ko not_active Ceased
- 2009-12-16 KR KR1020167030350A patent/KR20160129915A/ko not_active Ceased
- 2009-12-16 MY MYPI20112413 patent/MY152669A/en unknown
- 2009-12-16 EP EP13177190.9A patent/EP2676953B1/en active Active
- 2009-12-16 CA CA2747437A patent/CA2747437C/en active Active
- 2009-12-16 SI SI200930750T patent/SI2379497T1/sl unknown
- 2009-12-16 PT PT131771909T patent/PT2676953T/pt unknown
- 2009-12-16 SI SI200931675A patent/SI2676953T1/sl unknown
- 2009-12-16 AU AU2009335924A patent/AU2009335924B2/en active Active
- 2009-12-16 KR KR1020187000381A patent/KR101885052B1/ko not_active Expired - Fee Related
- 2009-12-16 CN CN2009801512748A patent/CN102256943A/zh active Pending
- 2009-12-16 PE PE2011001226A patent/PE20120336A1/es not_active Application Discontinuation
- 2009-12-16 PE PE2014001111A patent/PE20142374A1/es not_active Application Discontinuation
- 2009-12-16 IL IL253845A patent/IL253845B/en unknown
- 2009-12-16 MX MX2011006609A patent/MX2011006609A/es active IP Right Grant
- 2009-12-16 KR KR1020167013818A patent/KR20160064245A/ko not_active Ceased
- 2009-12-16 DK DK13177190.9T patent/DK2676953T3/en active
- 2009-12-16 JP JP2011542351A patent/JP5627597B2/ja active Active
- 2009-12-16 CN CN201510102280.1A patent/CN104803902A/zh active Pending
- 2009-12-16 LT LTEP13177190.9T patent/LT2676953T/lt unknown
- 2009-12-16 HR HRP20131106AT patent/HRP20131106T1/hr unknown
- 2009-12-16 KR KR1020177014691A patent/KR20170062554A/ko not_active Ceased
- 2009-12-16 RU RU2011129222A patent/RU2518114C3/ru active Protection Beyond IP Right Term
- 2009-12-16 NZ NZ593061A patent/NZ593061A/xx not_active IP Right Cessation
- 2009-12-16 RS RS20130510A patent/RS53041B/sr unknown
- 2009-12-16 PL PL13177190T patent/PL2676953T3/pl unknown
- 2009-12-16 US US13/140,478 patent/US20120115840A1/en not_active Abandoned
- 2009-12-16 ES ES13177190.9T patent/ES2631203T3/es active Active
- 2009-12-16 UY UY0001032330A patent/UY32330A/es not_active Application Discontinuation
- 2009-12-16 DK DK09793413.7T patent/DK2379497T3/da active
- 2009-12-16 PL PL09793413T patent/PL2379497T3/pl unknown
- 2009-12-16 SG SG2011036886A patent/SG171785A1/en unknown
- 2009-12-16 PT PT97934137T patent/PT2379497E/pt unknown
- 2009-12-16 IL IL294514A patent/IL294514A/en unknown
- 2009-12-16 EP EP09793413.7A patent/EP2379497B1/en active Active
- 2009-12-16 MA MA34008A patent/MA32961B1/fr unknown
- 2009-12-16 CA CA2951479A patent/CA2951479A1/en not_active Abandoned
- 2009-12-16 RS RS20170599A patent/RS56110B1/sr unknown
- 2009-12-16 HU HUE13177190A patent/HUE034819T2/en unknown
- 2009-12-16 WO PCT/US2009/068143 patent/WO2010080409A1/en not_active Ceased
- 2009-12-16 BR BRPI0923176A patent/BRPI0923176B8/pt active IP Right Grant
- 2009-12-16 ES ES09793413T patent/ES2436197T3/es active Active
- 2009-12-16 AR ARP090104917A patent/AR074694A1/es not_active Application Discontinuation
- 2009-12-17 TW TW103142662A patent/TWI591055B/zh active
- 2009-12-17 TW TW098143443A patent/TWI500603B/zh active
- 2009-12-17 JO JO2009488A patent/JO2894B1/en active
-
2011
- 2011-05-20 ZA ZA2011/03709A patent/ZA201103709B/en unknown
- 2011-05-23 IL IL213071A patent/IL213071A0/en unknown
- 2011-06-17 CL CL2011001490A patent/CL2011001490A1/es unknown
- 2011-06-23 CO CO11079284A patent/CO6390104A2/es not_active Application Discontinuation
- 2011-07-15 EC EC2011011210A patent/ECSP11011210A/es unknown
-
2013
- 2013-06-12 US US13/915,941 patent/US20140005162A1/en not_active Abandoned
- 2013-11-20 CY CY20131101026T patent/CY1114662T1/el unknown
-
2015
- 2015-03-03 US US14/636,248 patent/US20150175536A1/en not_active Abandoned
-
2017
- 2017-06-14 HR HRP20170916TT patent/HRP20170916T1/hr unknown
- 2017-06-22 CY CY20171100669T patent/CY1119037T1/el unknown
- 2017-10-31 US US15/799,235 patent/US20180118678A1/en not_active Abandoned
-
2018
- 2018-07-10 AR ARP180101916 patent/AR112227A2/es unknown
-
2020
- 2020-11-11 US US17/095,052 patent/US20210323915A1/en not_active Abandoned
-
2021
- 2021-03-22 AR ARP210100712A patent/AR121635A2/es unknown
-
2022
- 2022-08-10 US US17/818,889 patent/US20230357142A9/en not_active Abandoned
-
2024
- 2024-02-06 US US18/434,514 patent/US20240239743A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2676953T3 (pl) | Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego | |
| EP2303918A4 (en) | METHOD FOR DOSED ADMINISTRATION OF A ACTIVIN ACTRIIA ANTAGONIST AND OBSERVATION OF TREATED PATIENTS | |
| IL236731A0 (en) | A method for analyzing cardiac arrhythmias | |
| ZA201103759B (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| IL200956A (en) | 1– [2– (2,4 – dimethylphenylsulfonyl) –phenyl] piperazine for the treatment of pain | |
| IL194975A0 (en) | Composition and methods for treatment of congestive heart failure | |
| ZA201006523B (en) | (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-prrrol-3-yl}-acrylamide salts | |
| IL212404A0 (en) | Compounds for treating ophthalmic diseases and disorders | |
| IL208004A0 (en) | Compounds and methods for reducing uric acid | |
| IL208254A0 (en) | Substituted pyrrolidine and piperdine compounds derivatives thereof, and methods for treating pain | |
| SI2307000T1 (sl) | Kombinacija pilokarpina in metimazola za zdravljenje charcot-marie- toothove bolezni in z njo povezanih nepravilnosti | |
| IL212966A (en) | Pyrazole-1-yl-methyl-cyclohexyl-acetic acid compounds, pharmaceutical preparations containing them, use of pharmaceutical preparation compounds and compounds for use in treatment method | |
| GB0915259D0 (en) | Sulphur-linked compounds for treating ophthalmic diseases and disorders | |
| ZA201103576B (en) | Hsp90 inhibitors for therapeutic treatment | |
| HU0800775D0 (en) | New yeastmushroom and process for hidrancing fruit storage disease | |
| HK1158973A (en) | Hsp90 inhibitors for therapeutic treatment | |
| GB0801140D0 (en) | Diary and method for medical monitoring | |
| GB0811492D0 (en) | rotating and telesopic patient assist bar(ratpab) | |
| GB0800488D0 (en) | Use of opioid compounds in wound healing | |
| AU2008903656A0 (en) | Method for improving renal function in cardiac surgery patients | |
| HK1144810A (en) | Indole compounds and methods for treating visceral pain |